Clinical Prior Authorization for Oxbryta in Traditional Medicaid Begins Sept. 8, 2020
VDP will implement the clinical prior authorization criteria for Oxbryta (voxelotor) for traditional Medicaid on Sept. 8. The Texas Drug Utilization Review Board approved Oxbryta as part of the Sickle Cell Disease Agents criteria (PDF) at its Jan. 2020 meeting. This prior authorization is optional for Medicaid managed care. The Pharmacy Clinical Prior Authorization Assistance Chart (PDF) shows the prior authorization each MCO uses and how those authorizations relate to traditional Medicaid claim processing. This chart is updated quarterly and available on the VDP website. For FirstCare clinical edits please click here.
* Required field
ATTENTION: By clicking “Continue”, you will be leaving the FirstCare Medicare Dual SNP (HMO SNP) site pages. If you wish to remain on these pages, simply click “Cancel” or close this box.